Immuron - FY25 global sales exceed projection, up 49% on prior year

Rhea-AI Summary

Immuron Limited (NASDAQ: IMRN), a biopharmaceutical company, reported exceptional FY25 global sales growth of 49% for its over-the-counter immune supplement Travelan, reaching AUD$7.3 million in total sales.

The company achieved strong performance across key markets with Australian sales reaching AUD$5.2 million (up 40% year-over-year) and North American sales hitting AUD$2.0 million (up 76% year-over-year). The June 2025 quarter showed continued momentum with total sales of AUD$2.0 million, representing a 55% increase from the previous year.

Growth was driven by increased consumer engagement, enhanced pharmacy visibility in Australia, and improved targeted communication in North America, particularly through Amazon sales channels and Canadian distribution expansion.

Positive

• Record global sales of AUD$7.3 million, exceeding projections with 49% YoY growth
• Strong North American performance with 76% YoY growth to AUD$2.0 million
• Australian market growth of 40% YoY to AUD$5.2 million
• Successful expansion into Canadian market
• Travelan becoming one of the fastest growing pharmacy brands in Australia

Negative

• None.

Insights

Financial Analyst

Immuron reports outstanding FY25 sales growth of 49%, significantly outperforming in North America with 76% increase.

Immuron Limited has delivered exceptional sales performance for FY25, reporting AUD$7.3 million in global sales, a remarkable 49% increase compared to the previous year. This growth substantially exceeded management's projections, demonstrating strong market traction for their flagship product Travelan®, an over-the-counter GI tract immune supplement.

Breaking down the geographic performance, Australia remains the dominant market with AUD$5.2 million in annual sales (40% growth), while North America showed the most impressive growth rate at 76%, reaching AUD$2.0 million. The June 2025 quarter was particularly strong, with total sales of AUD$2.0 million representing a 55% year-over-year increase.

The company's strategic focus on consumer engagement and pharmacy visibility in Australia has positioned Travelan as one of the fastest-growing pharmacy brands in that market. Meanwhile, the North American strategy of targeted Amazon sales and expanded Canadian distribution is clearly paying dividends.

Management's forward-looking statements indicate continued investment in North American expansion while maintaining growth momentum in Australia. This dual-market approach leverages their established Australian presence while capitalizing on the higher growth rates and larger market potential in North America. The sequential quarterly growth pattern suggests their commercialization strategy is gaining traction across all markets.

This sales performance is particularly noteworthy for a specialty biopharmaceutical product in the travel health segment, indicating strong consumer demand and successful marketing execution despite operating in a niche market. The consistent growth across geographic regions validates Immuron's international commercialization strategy and suggests potential for continued expansion.

Sales Highlights (unaudited):

Global	Annual sales AUD$7.3 million up 49% on prior year June 2025 Quarter AUD$2.0 million up 55% on prior year
Australia	Annual sales AUD$5.2 million up 40% on prior year June 2025 Quarter AUD$1.5 million up 58% on prior year
North America	Annual sales AUD$2.0 million up 76% on prior year June 2025 Quarter AUD$0.5 million up 49% on prior year

MELBOURNE, Australia, July 17, 2025 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company, is pleased to announce continued sales growth (unaudited) of Travelan^®, an over-the-counter immune supplement that targets pathogenic bacteria and the toxins they produce in the gastrointestinal (GI) tract.

Flavio Palumbo, Chief Commercial Officer, said, “Immuron has exceeded sales projections and achieved record FY25 sales of A$7.3 million, with growth just shy of 50% on last year. In FY25, we set out to make Travelan the must-have travel essential for consumers and retailers. This is a fantastic result, supporting our clear growth strategy. Australia, on the back of increased consumer engagement and a clear pharmacy visibility program, achieved annual sales of A$5.2 million, growth of 40% on last year. Travelan is now one of the fastest growing brands in pharmacy in Australia. Our North American business continues to produce record results with strong USA sales to Amazon with improved, more targeted communication focused on the benefits of Travelan driving more users into the brand. This, together with establishing good distribution of Travelan in Canada, resulted in North American sales of A$2 million, growth of 76% on last year. We have achieved record Travelan sales in all markets. In FY26, we will invest to grow in North America while continuing the momentum in Australia.”

This release has been authorised by the directors of Immuron Limited.

Steven Lydeamore
Chief Executive Officer
steve@immuron.com

About Travelan^®
Travelan^® is an orally administered passive immunotherapy that prophylactically reduces the likelihood of contracting travelers’ diarrhea, a digestive tract disorder that is commonly caused by pathogenic bacteria and the toxins they produce. Travelan^® is a purified tablet preparation of hyper-immune bovine antibodies and other factors, which when taken with meals bind to diarrhea-causing bacteria and prevent colonization and the pathology associated with traveler’s diarrhea. In Australia, Travelan^® is a listed medicine on the Australian Register for Therapeutic Goods (AUST L 106709) and is indicated to reduce the risk of Traveler’s Diarrhea, reduce the risk of minor gastro-intestinal disorders and is antimicrobial. In Canada, Travelan^® is a licensed natural health product (NPN 80046016) and is indicated to reduce the risk of Traveler’s Diarrhea. In the U.S., Travelan^® is sold as a dietary supplement for digestive tract protection.

About Traveler’s diarrhea
Traveler’s Diarrhea is a gastrointestinal infection with symptoms that include loose, watery (and occasionally bloody) stools, abdominal cramping, bloating, and fever, Enteropathogenic bacteria are responsible for most cases, with enterotoxigenic Escherichia coli (ETEC) playing a dominant causative role.

About Immuron
Immuron Limited (ASX: IMC, NASDAQ: IMRN) is an Australian biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of inflammatory mediated and infectious diseases.

For more information visit: https://www.immuron.com.au

FORWARD-LOOKING STATEMENTS:

This press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock value. Factors that could cause actual results to differ materially from those currently anticipated include: risks relating to our growth strategy; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; risks relating to the results of research and development activities; risks relating to the timing of starting and completing clinical trials; uncertainties relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.

A photo accompanying this announcement is available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/d24a5b18-311e-4dc1-b624-1162a4d7acc9

FAQ

What were Immuron's (NASDAQ:IMRN) FY25 global sales results?

Immuron reported global sales of AUD$7.3 million for FY25, representing a 49% increase compared to the previous year.

How did Immuron perform in the North American market in FY25?

Immuron's North American sales reached AUD$2.0 million, showing strong growth of 76% year-over-year, driven by improved Amazon sales in the USA and expanded distribution in Canada.

What were Immuron's Australian sales figures for FY25?

In Australia, Immuron achieved sales of AUD$5.2 million, representing a 40% increase from the previous year, supported by increased consumer engagement and enhanced pharmacy visibility.

How did Immuron perform in the June 2025 quarter?

For the June 2025 quarter, Immuron reported total sales of AUD$2.0 million, marking a 55% increase compared to the same quarter in the previous year.

What is Travelan and how is it contributing to Immuron's growth?

Travelan is an over-the-counter immune supplement that targets pathogenic bacteria and toxins in the gastrointestinal tract. It has become one of the fastest growing brands in Australian pharmacies and is showing strong growth across all markets.